Hydroxychloroquine is one of the more remarkable medicines in long-term use for lupus, rheumatoid arthritis, and related autoimmune conditions. It descends from quinine, itself drawn from the bark of the South American cinchona tree, and its ability to quiet an overactive immune system has kept it in steady use for more than sixty years. But that same long service life is precisely why it carries a well-documented and well-studied risk to the retina. This article explains what the current ophthalmology guidelines require for monitoring that risk, why the screening schedule looks the way it does, and what informed patients should expect from their own eye care.

Why the Retina Is Vulnerable

Hydroxychloroquine accumulates preferentially in the retinal pigment epithelium, the layer of cells that supports and nourishes the light-sensing photoreceptors. The drug binds to melanin in these cells and is cleared very slowly, so with years of continuous use it can build up to concentrations that interfere with normal cellular housekeeping, particularly the lysosomal processes that clear cellular debris. Over time this can damage photoreceptors in a ring around the fovea, producing the classic "bull's-eye" pattern of pigment loss seen on retinal imaging. This is a cumulative, dose- and duration-dependent process, not an acute allergic reaction, which is exactly why screening is built around time on the drug and total exposure rather than a single early test.

Once retinal damage becomes visible to the naked eye on a standard dilated exam, some of it is already irreversible, and it can continue to progress for a period even after the drug is stopped. The entire logic of modern screening is to catch subtle, subclinical changes on sensitive instrument-based tests well before a patient notices any change in vision and well before damage is visible to routine ophthalmoscopy.

What the Guidelines Actually Require

The American Academy of Ophthalmology issued its current framework in a 2016 revision of earlier 2011 recommendations, led by ophthalmologist Michael Marmor and colleagues, published in the journal Ophthalmology. The revision tightened the dosing threshold considerably: rather than basing risk on 6.5 mg/kg of ideal body weight per day, as older guidance did, the current standard uses 5 mg/kg of the patient's actual body weight per day. This matters practically because dosing by ideal body weight tended to under-recognize risk in smaller patients, and the shift to real body weight closes that gap.

The core recommendations are:

Major risk factors that move a patient into earlier, annual screening include a daily dose above the 5 mg/kg real-body-weight threshold, kidney impairment (because the kidneys are a primary route of drug clearance), concurrent use of tamoxifen, and pre-existing retinal or macular disease that would make it harder to distinguish drug-related change from baseline pathology. Duration of use beyond five years remains the single strongest driver of risk in the absence of these other factors.

The Evidence Behind the Numbers

The tightened thresholds were not adopted casually. A key piece of evidence came from a large retrospective cohort study conducted through Kaiser Permanente Northern California and published in JAMA Ophthalmology in 2014 by Ronald Melles and Michael Marmor. The study examined more than two thousand patients who had used hydroxychloroquine continuously for at least five years and screened them with modern, sensitive retinal imaging. Overall prevalence of definite retinopathy across the whole group was about 7.5 percent, but the risk was very unevenly distributed. Among patients who had taken the drug for less than a decade, prevalence was under two percent; among those who had used it for more than twenty years, prevalence rose to nearly one in five. Risk also rose sharply with daily dose above the 5 mg/kg real-body-weight line, which is the finding that directly informed the revised dosing threshold.

This is a strong piece of human evidence: a large, real-world cohort using contemporary detection methods, not an animal model or a small case series. It is also consistent with decades of smaller case reports and mechanistic work in cell and animal models showing that chloroquine-class drugs concentrate in pigmented ocular tissue and disrupt lysosomal function. Where the evidence is thinner is in predicting which individual patient, at a given dose and duration, will actually develop toxicity — the population-level curves are well established, but individual susceptibility varies, and genetics likely plays some role that is not yet fully mapped.

The Tests That Actually Detect Early Damage

One of the more important shifts in the 2016 guidance was moving away from reliance on the Amsler grid and basic ophthalmoscopy, both of which are too insensitive to catch early, pre-symptomatic disease. The current standard combines two primary tests, supplemented by others where available:

One detail with real-world consequence: patients of Asian descent have been observed in several case series to develop damage in a pattern that extends further from the fovea than the classic bull's-eye, sometimes sparing the central macula while affecting a wider ring. Because of this, the guidelines recommend wider-field visual field testing, such as a 24-2 or 30-2 pattern, in addition to the standard 10-2 test for these patients, so that damage outside the central field is not missed.

Who Carries the Highest Risk, and What That Means for Follow-Up

Not every long-term user faces the same risk, and the guidelines are built to reflect that rather than treating everyone identically. The clearest risk multipliers, drawn from the cohort evidence described above, are:

For patients without any of these additional factors, five years of annual dilated exams plus baseline testing is a reasonable, evidence-based schedule, and it reflects a real judgment that intensive annual screening from day one for every patient would not meaningfully improve outcomes for the low-risk majority while adding cost and burden. For patients who do carry additional risk factors, the case for annual screening from the start is much stronger, and this is a conversation worth having directly and specifically with the prescribing physician and the eye care provider, rather than assuming a one-size schedule applies.

What This Means in Practice

None of this is a reason to avoid a medicine that, for the right patient, controls a serious autoimmune disease effectively and has been used safely by a great many people for a great many years. It is, instead, a case for taking the maintenance side of long-term therapy seriously — showing up for the baseline exam, keeping the annual appointments once they are due, and making sure the ophthalmologist doing the testing actually knows the patient is on hydroxychloroquine and for how long, since that context changes which tests are ordered. Hydroxychloroquine is not approved by the FDA for COVID-19 treatment or prevention, and nothing here should be read as bearing on that separate and unresolved question; this article concerns its established, approved uses in rheumatologic and dermatologic disease, where the retinal risk profile has been studied over a long period. Patients and families managing a chronic illness are the ones best positioned, working with a physician they trust, to weigh this manageable risk against the real benefit the drug provides — and a body worth stewarding is worth the modest discipline of an annual eye exam.

Key takeaway: For patients on long-term hydroxychloroquine, annual instrument-based retinal screening — beginning at five years for most, and sooner for those with added risk factors — is the guideline-supported way to catch damage while it is still preventable, and it deserves the same consistency a patient gives to the medicine itself.